查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
扁桃體和腺樣體切除術產品市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1273495

扁桃體和腺樣體切除術產品市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Tonsil and Adenoid Removal Products Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，扁桃體和腺樣體切除術產品市場的複合年增長率預計為 7.3%。

COVID-19 大流行最初對扁桃體和腺樣體切除術產品市場產生了重大影響。 實施封鎖以及推遲非緊急手術和非 COVID 相關治療減少了 2020 年扁桃體和腺樣體手術的數量。 由於 COVID-19 的高風險，各種耳鼻喉科服務受到限制，僅優先考慮必要的手術和程序。 例如，2022 年 2 月發表在《頭頸雜誌》(Journal of Head and Neck) 上的一項研究發現，大流行使德國扁桃體手術的數量減少了多達 82%。 根據 2021 年 7 月發表在 Journal Laryngoscope Investigative Otolaryngology 上的一項研究，隨著大流行期間擇期手術的延誤和取消。 據說 COVID-19 封鎖降低了兒童和其他人扁桃體感染的發生率，也導致兒童鼓膜切開術和扁桃體手術的數量減少。 然而，即使在大流行期間，也允許並進行嚴重病例的扁桃體手術。 例如，在 2020 年 5 月發表在《歐洲耳鼻咽喉頭頸疾病年鑑》上的一項研究中，扁桃體切除術和腺樣體切除術在患有嚴重阻塞性睡眠呼吸暫停的成年人中毫不拖延地進行了。我是。 然而，隨著封鎖的解除和非 COVID 緊急情況下選擇性措施的恢復，市場有望恢復其 COVID 前的正常步伐。 例如，2022 年 2 月，新南威爾士州政府宣布恢復非緊急擇期手術，將患者在私立醫院的住院時間增加到大流行前活動水平的 85%。 此外，2022 年 5 月，紐約州衛生部 (DOH) 宣佈在醫院、辦公室外科診所、診斷和治療中心以及門診手術中心重新開放非緊急程序和非緊急擇期手術。我們更新了指南。

隨著 COVID 的解除以及非緊急和擇期手術在全球範圍內的恢復，預計市場將以更穩定的速度增長。

此外，扁桃體和腺樣體感染的增加也在推動市場增長。 2022 年 6 月發表在《柳葉刀》雜誌上的一項研究發現，計算得出的兒童 A 組鏈球菌咽部感染的合併發生率為每 100 隻幼崽咽炎和 A 組溶血 82.2 次。鏈球菌每 100 小牛年發生 22.1 次。 2022 年 12 月發表在《自然》雜誌上的一項研究警告說，2022 年 12 月英國超過 13 名兒童的死亡人數可能導致致命的猩紅熱引起的 A 型鏈球菌病例激增。強調。 根據 2021 STAT Pearls，腺樣體增生在兒童中的患病率為 34.5%。

因此，由於扁桃體和腺樣體感染的流行率不斷上升，預計研究市場在分析期間將出現增長。 然而，與手術相關的並發症可能會阻礙市場增長。

扁桃體腺樣體切除產品市場趨勢

Coblation 部分預計在預測期內將顯著增長

Coblation 是一種受控的精密外科手術，它使用冷射頻波和鹽水去除腺樣體和扁桃體組織。 與傳統的腺樣體-扁桃體切除術相比，該手術有幾個優點。 與傳統的腺樣體/扁桃體切除術相比，低溫消融具有出血少、疼痛少的優點，常用於小兒腺樣體/扁桃體切除術的治療。 多項研究支持該手術的安全性和有效性，尤其是在治療兒童扁桃體和腺樣體方面。 2022 年 3 月發表在 Springer Nature Cureus 上的一項研究發現，消融技術可改善手術期間和手術後的結果。 該技術延遲了術後出血和術後疼痛，並在鎮痛給藥、飲食和扁桃體組織恢復方面提供了良好的效果。 2020 年 8 月發表在《國際兒科耳鼻喉科雜誌》上的一項研究強調了低溫囊內扁桃體切除術治療阻塞性睡眠呼吸暫停兒童復發性扁桃體炎的安全性和有效性。底部。 2022 年 2 月在 Research Square 發表的一項研究強調了冷卻技術在腺樣體扁桃體手術中的安全性和有效性，減少了自限性出血並將失血量控制在 0.7%。 該手術還消除了再次進行扁桃體手術的需要。

由於消融技術的良好術後效果及其在小兒腺樣體和扁桃體手術中的廣泛應用，預計該領域在預測期內將出現顯著增長。

扁桃體和腺樣體去除產品市場-IMG1

北美有望主導門診康復中心市場

由於扁桃體、腺樣體和呼吸道感染的高患病率以及大量手術等因素，預計北美將主導市場。 美國的呼吸道感染負擔也很高。 根據國家人口統計系統-2020年死亡數據，慢性下呼吸道疾病（包括哮喘）導致的死亡人數超過152657人。 據美國肺臟協會稱，截至 2022 年 11 月，美國將有超過 1250 萬成年人患有慢性阻塞性肺病。 該國每年進行大量腺樣體和扁桃體手術。 根據國家生物技術信息中心的數據，截至 2022 年 8 月，美國每年將進行超過 50 萬例扁桃體切除手術。 該地區的呼吸道感染患病率也很高，這也有助於對扁桃體和腺樣體器官進行手術干預。 根據美國疾控中心2023年2月公佈的數據，從2022年到2023年2月，美國將報告超過2500萬例與流感相關的疾病，超過28萬例住院治療，以及1.7萬例因流感死亡。 化膿性鏈球菌（A 組鏈球菌）是一種引起扁桃體炎的細菌，每年在美國感染超過 11,000 至 24,000 人，並引起鏈球菌和膿皰瘡等感染。

因此，預計扁桃體、腺樣體和呼吸道感染的高患病率將推動北美地區監測市場的增長。

扁桃體和腺樣體去除產品市場-IMG2

扁桃體和腺樣體切除術產品行業概況

扁桃體和腺樣體切除術產品市場競爭激烈，因為多家公司在全球和區域開展業務。 競爭格局包括幾家擁有全球和區域份額的知名企業，包括美敦力、博士倫公司、奧林巴斯美國、New Med Instruments、medelecsurgical、Smith&Nephew、Advin Health Care、Deluxe Scientific Surgico Pvt Ltd、Integra LifeSciences、EON Meditech。我對公司進行分析。

其他福利：

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 調查假設和市場定義
  • 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 扁桃體和腺樣體感染增加
    • 呼吸道感染增加
  • 市場製約因素
    • 與手術相關的並發症
  • 波特五力
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模）

  • 按產品類型
    • 扁桃體切除產品
      • 鑷子
      • 線環
      • 剪刀
    • 腺樣體去除劑
      • 微型清創器
  • 按技術
    • 電動手術刀 (ECT)
    • 消融
    • 和諧女
    • 其他技術
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Medtronic
    • BAUSCH & LOMB INCORPORATED.
    • Olympus America
    • New Med Instruments
    • medelecsurgical
    • Smith&Nephew
    • Advin Health Care
    • Deluxe Scientific Surgico Pvt Ltd
    • Integra LifeSciences
    • EON Meditech

第7章 市場機會與將來動向

簡介目錄
Product Code: 68868

The tonsil & adenoid removal products market is expected to register a CAGR of 7.3% over the forecast period.

The COVID-19 pandemic has had a substantial impact on the tonsil & adenoid removal products market initially. The imposition of lockdown and delay of non-urgent surgeries and non-COVID disease treatment decreased the number of tonsil and adenoid procedures in 2020. The high risk of COVID-19 led to prioritizing only critical surgeries and procedures, which restricted various otolaryngology services. For instance, in a study published in the Journal of Head and Neck in February 2022, the number of tonsil surgery decreased by up to 82% in Germany due to the pandemic. According to a study published in the Journal Laryngoscope Investigative Otolaryngology in July 2021, along with the delay and cancellation of elective surgeries during a pandemic. The COVID-19 lockdown decreased the incidence rates of tonsil infections, such as in children, which also led to a decrease in the volume of tympanostomies and tonsil surgeries in children. However, even during the pandemic, severe cases of tonsil surgeries were allowed and performed. For instance, in a study published in the European Annals of Otorhinolaryngology, Head and Neck Diseases in May 2020, tonsillectomy and adenoidectomy were performed without any delay in the case of severe obstructive sleep apnea syndrome in adults. Although, with the lifting of the lockdown and the resumption of the non-COVID, non-urgent, and elective procedures, the market is expected to regain its normal pace as it was in pre-COVID. For instance, in February 2022, the New South Wales Government announced the resumption of non-urgent elective surgeries and increased the overnight stay of the patients by 85% of pre-pandemic activity levels in the private hospitals. Further, in May 2022, the New York State Department of Health (DOH) announced the updated guideline for the resumption of nonurgent procedures and non-essential elective surgeries in hospitals, office-based surgery practices, diagnostic and treatment centers, and ambulatory surgery centers.

The market is expected to grow further at a stable pace with the lifting of the lockdown and the resumption of the non-COVID, non-urgent, and elective procedures globally.

Further, the increasing cases of tonsil and adenoid infections are also boosting the market's growth. According to a study published in the Lancet in June 2022, the pooled incidence rate of the group A Streptococcus throat infection calculated for children was 82.2 episodes per 100 child years for sore throat and 22.1 episodes per 100 child years for Strep A sore throat. A study published in Journal Nature in December 2022 has underlined the risk of the surging case of strep A after the death of over 13 children in the United Kingdom in the month of December 2022, which causes deadly scarlet fever. According to the STAT Pearls in 2021, the condition of adenoid hypertrophy has a prevalence rate of 34.5% in children.

Therefore, owing to the increasing prevalence of tonsil and adenoid infections, the studied market is anticipated to witness growth over the analysis period. However, the complication associated with the surgeries is likely to impede the market growth.

Tonsil and Adenoid Removal Products Market Trends

The Coblation Segment is Expected to Witness Significant Growth Over the Forecast Period

Coblation, also known as controlled ablation, is a controlled and precise surgical procedure for the removal of the adenoid and tonsil tissue by using low-temperature radiofrequency and a saline solution. The technique has several advantages over traditional adenotonsillectomy procedures. The coblation technique is highly adopted for the management of adenoid and tonsil infections in children because of its advantage of lower bleeding and pain, as compared to traditional adenotonsillectomy procedures. Several studies have supported the safety and efficacy of the technique for tonsil and adenoid procedures, especially in children. According to a study published in the Springer Nature Cureus in March 2022, the coblation technique offers improved outcomes during surgery and post-surgery recovery. The technique caused delayed hemorrhage and post-operative pain after the surgery and offered favorable outcomes in the delivery of analgesia, diet, and tonsillar tissue recovery. A study published in the International Journal of Pediatric Otorhinolaryngology in August 2020 highlighted the safety and efficacy of the coblation intracapsular tonsillectomy for recurrent tonsillitis in children with the condition of obstructive sleep apnea. A study published in Research Square in February 2022 highlighted the safety and efficacy of the coblation technique for adenotonsillar surgery, which reduced self-limited bleeding and controlled blood loss by 0.7%. The procedure also eliminated the need for another tonsillar surgery.

With the desirable post-operative outcome of the coblation technique and its wide usage in pediatric adenoid and tonsil procedures, the segment is expected to witness significant growth over the forecast period.

Tonsil and Adenoid Removal Products Market - IMG1

North America is Expected to Dominate the Outpatient Rehabilitation Centers Market

North America is expected to dominate the market owing to factors such as a high prevalence of tonsil, adenoid, and respiratory infections and a high volume of surgical procedures in the region. The United States has a high burden of respiratory infections as well. According to the National Vital Statistics System - Mortality Data in 2020, over 152,657 deaths happened due to chronic lower respiratory diseases (including asthma). According to the American Lung Association, in November 2022, over 12.5 million adults in the United States are living with the condition of chronic obstructive pulmonary disease. The country has a high volume of surgical procedures of adenoid and tonsil procedures performed every year. According to the National Center for Biotechnology Information, in August 2022, over 500,000 procedures of tonsillectomies were performed every year in the United States. The region also has a high prevalence of respiratory infections which also contributes to the surgical interventions of the tonsil and adenoid organs. According to data published by the CDC in February 2023, over 25 million cases of influenza-associated illnesses, over 280,000 hospitalizations, and 17,000 deaths were reported due to influenza in the United States in the year 2022 and till February 2023. The tonsilitis-causing bacterium Streptococcus pyogenes (group A Streptococcus) affects over 11,000-24,000 individuals, with the Group A streptococcal causing infections such as strep throat and impetigo in the United States each year.

Therefore, owing to the high prevalence of tonsil, adenoid, and respiratory infections, it is expected to boost the growth of the studied market in the North America Region.

Tonsil and Adenoid Removal Products Market - IMG2

Tonsil and Adenoid Removal Products Industry Overview

The tonsil & adenoid removal products market is moderately competitive in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of several international as well as local companies which hold market shares and are well known, including Medtronic, BAUSCH & LOMB INCORPORATED, Olympus America, New Med Instruments, medelecsurgical, Smith&Nephew, Advin Health Care, Deluxe Scientific Surgico Pvt Ltd, Integra LifeSciences, and EON Meditech.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Infecton in Tonsils and Adenoid
    • 4.2.2 Increasing number of Respiratory Tract Infection
  • 4.3 Market Restraints
    • 4.3.1 Complication Associated with the Surgeries
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Tonsils Removal Products
      • 5.1.1.1 Forceps
      • 5.1.1.2 Wire loop
      • 5.1.1.3 Scissors
    • 5.1.2 Adenoid Removal Products
      • 5.1.2.1 Microdebrider
  • 5.2 By Technology
    • 5.2.1 Electrocautery (ECT)
    • 5.2.2 Coblation
    • 5.2.3 Harmonic scalpel
    • 5.2.4 Other Technologies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Medtronic
    • 6.1.2 BAUSCH & LOMB INCORPORATED.
    • 6.1.3 Olympus America
    • 6.1.4 New Med Instruments
    • 6.1.5 medelecsurgical
    • 6.1.6 Smith&Nephew
    • 6.1.7 Advin Health Care
    • 6.1.8 Deluxe Scientific Surgico Pvt Ltd
    • 6.1.9 Integra LifeSciences
    • 6.1.10 EON Meditech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS